2. Academic Validation
  3. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration

Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration

  • Parasit Vectors. 2014 Mar 6;7:86. doi: 10.1186/1756-3305-7-86.
Feli M Walther 1,  Allan J Paul,  Mark J Allan,  Rainer K A Roepke,  Martin C Nuernberger
Affiliations

Affiliation

  • 1 MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany. [email protected].
PMID: 24602342 DOI: 10.1186/1756-3305-7-86
Abstract

Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control after a single oral dose. This study investigated the safety of oral administration of fluralaner at 3 times the highest expected clinical dose to Multi Drug Resistance Protein 1 (MDR1(-/-)) gene defect Collies.

Methods: Sixteen Collies homozygous for the MDR1 deletion mutation were included in the study. Eight Collies received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed Collies served as controls. All Collies were clinically observed until 28 days following treatment.

Results: No adverse events were observed subsequent to fluralaner treatment of MDR1(-/-) Collies at three times the highest expected clinical dose.

Conclusions: Fluralaner chewable tablets are well tolerated in MDR1(-/-) Collies following oral administration.

Figures
Products